Karista | Investing in Game Changers

OUR WAY

Karista is an early-stage venture capital firm created in 2001. We funded 90+ companies over the past two decades and support tomorrow’s game changers in the field of Health, Digital, Tech, and NewSpace.

We have always worked to provide more than cash and partnered with entrepreneurs whom we share a common vision with.

OUR WAY

OUR COMPANIES

Vestack

Tech

By combining digital design, bio-based materials, and modular manufacturing, Vestack is a PropTech company producing buildings faster and at lower cost, while drastically reducing the building’s environmental footprint.

Exotrail

Tech

Exotrail’s mission is to deliver agility to the space industry. The company provides mission simulation and operation software, high thrust and flexible electric propulsion systems, and on-orbit transfer vehicles.

moveUP

Healthcare

MoveUp develops data-driven personalized remote digital care for post-acute out-patients, delivering similar clinical outcomes at a lower cost, while enabling healthcare professionals to focus on more complex patients or urgent situations.

NEWS

— ALL NEWS & Insights

Jul 15 th, 2021

False subscription forms usurping the identity of Karista

Warning - We would like to draw your attention to the existence of false subscription forms usurping the identity of Karista. Please note that we never sign a subscription document in advance. If you have any doubts and before signing any form, please contact us.

Jul 5 th, 2021

Successful first in human implantations of Topaz

TRiCares is pleased to announce the successful first in human implantations of its Topaz transfemoral tricuspid heart valve replacement system.This announcement marks the successful first two implantations of Topaz in patients, which were done on a compassionate use basis.

Jul 1 st, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, just announced the end of recruitment in ACTIMIS, its phase 1b/2a study with glenzocimab (ACT017), a novel humanized monoclonal antibody fragment for use in patients with acute ischemic stroke.